Corbus Pharmaceuticals Holdings Company Profile (NASDAQ:CRBP)

About Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

Corbus Pharmaceuticals Holdings logoCorbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's product, anabasum is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Anabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing anabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CRBP
  • CUSIP: N/A
  • Web: www.corbuspharma.com
Capitalization:
  • Market Cap: $344.01 million
  • Outstanding Shares: 50,220,000
Average Prices:
  • 50 Day Moving Avg: $6.51
  • 200 Day Moving Avg: $6.90
  • 52 Week Range: $4.65 - $10.78
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.54
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $2.76 million
  • Price / Sales: 124.64
  • Book Value: $0.75 per share
  • Price / Book: 9.13
Profitability:
  • EBIDTA: ($27,540,000.00)
  • Net Margins: -1,001.77%
  • Return on Equity: -107.10%
  • Return on Assets: -83.38%
Debt:
  • Current Ratio: 6.37%
  • Quick Ratio: 6.37%
Misc:
  • Average Volume: 567,062 shs.
  • Beta: 2.43
  • Short Ratio: 15.29
 

Frequently Asked Questions for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

What is Corbus Pharmaceuticals Holdings' stock symbol?

Corbus Pharmaceuticals Holdings trades on the NASDAQ under the ticker symbol "CRBP."

How were Corbus Pharmaceuticals Holdings' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) posted its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.15) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.19) by $0.04. The business earned $0.35 million during the quarter, compared to analyst estimates of $0.50 million. Corbus Pharmaceuticals Holdings had a negative net margin of 1,001.77% and a negative return on equity of 107.10%. View Corbus Pharmaceuticals Holdings' Earnings History.

Where is Corbus Pharmaceuticals Holdings' stock going? Where will Corbus Pharmaceuticals Holdings' stock price be in 2017?

4 analysts have issued 12-month price targets for Corbus Pharmaceuticals Holdings' stock. Their forecasts range from $12.00 to $27.00. On average, they anticipate Corbus Pharmaceuticals Holdings' share price to reach $20.50 in the next twelve months. View Analyst Ratings for Corbus Pharmaceuticals Holdings.

Who are some of Corbus Pharmaceuticals Holdings' key competitors?

Who are Corbus Pharmaceuticals Holdings' key executives?

Corbus Pharmaceuticals Holdings' management team includes the folowing people:

  • Mark A. Tepper Ph.D., President, Chief Scientific Officer
  • Yuval Cohen, Chief Executive Officer, Director
  • Sean F. Moran CPA, Chief Financial Officer
  • Barbara White M.D., Chief Medical Officer
  • David P Hochman, Director
  • Avery W. Catlin CPA, Independent Director
  • Renu Gupta M.D., Independent Director
  • Alan F. Holmer J.D., Independent Director

Who owns Corbus Pharmaceuticals Holdings stock?

Corbus Pharmaceuticals Holdings' stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.11%), IFP Advisors Inc (1.99%), FMR LLC (1.83%), State Street Corp (1.17%), Northern Trust Corp (0.96%) and Raymond James Financial Services Advisors Inc. (0.85%). Company insiders that own Corbus Pharmaceuticals Holdings stock include Alan F Holmer, Barbara White, David P Hochman, Sean F Moran and Yuval Cohen. View Institutional Ownership Trends for Corbus Pharmaceuticals Holdings.

Who sold Corbus Pharmaceuticals Holdings stock? Who is selling Corbus Pharmaceuticals Holdings stock?

Corbus Pharmaceuticals Holdings' stock was sold by a variety of institutional investors in the last quarter, including IFP Advisors Inc and FMR LLC. View Insider Buying and Selling for Corbus Pharmaceuticals Holdings.

Who bought Corbus Pharmaceuticals Holdings stock? Who is buying Corbus Pharmaceuticals Holdings stock?

Corbus Pharmaceuticals Holdings' stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Northern Trust Corp, Vanguard Group Inc., Artal Group S.A., TIAA CREF Investment Management LLC, Bank of New York Mellon Corp, Teachers Advisors LLC and California State Teachers Retirement System. Company insiders that have bought Corbus Pharmaceuticals Holdings stock in the last two years include Alan F Holmer, Barbara White, David P Hochman, Sean F Moran and Yuval Cohen. View Insider Buying and Selling for Corbus Pharmaceuticals Holdings.

How do I buy Corbus Pharmaceuticals Holdings stock?

Shares of Corbus Pharmaceuticals Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corbus Pharmaceuticals Holdings' stock price today?

One share of Corbus Pharmaceuticals Holdings stock can currently be purchased for approximately $6.85.


MarketBeat Community Rating for Corbus Pharmaceuticals Holdings (NASDAQ CRBP)
Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  123 (Vote Outperform)
Underperform Votes:  37 (Vote Underperform)
Total Votes:  160
MarketBeat's community ratings are surveys of what our community members think about Corbus Pharmaceuticals Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $20.50 (199.27% upside)

Analysts' Ratings History for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/20/2017Cantor FitzgeraldReiterated RatingBuy$24.00HighView Rating Details
8/9/2017Noble FinancialReiterated RatingBuyLowView Rating Details
4/3/2017JMP SecuritiesReiterated RatingOutperform$20.00 -> $27.00LowView Rating Details
11/30/2016AegisReiterated RatingBuy$12.00N/AView Rating Details
(Data available from 9/25/2015 forward)

Earnings

Earnings History for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Earnings by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Earnings History by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ CRBP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017($0.19)($0.15)$0.50 million$0.35 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.16)($0.16)$2.50 million$1.29 millionViewN/AView Earnings Details
3/9/2017Q4 2016($0.12)($0.18)$1.50 million$0.38 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.10)($0.12)$1.00 million$0.74 millionViewN/AView Earnings Details
8/15/2016Q216($0.08)($0.11)$1.25 million$0.40 millionViewN/AView Earnings Details
5/16/2016Q116($0.08)($0.08)$0.40 millionViewN/AView Earnings Details
11/10/2015Q315($0.08)($0.06)$0.17 millionViewN/AView Earnings Details
8/13/2015Q2 2015($0.06)($0.10)$0.11 millionViewN/AView Earnings Details
2/10/2015Q4 2014($0.03)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Current Year EPS Consensus Estimate: $-0.63 EPS
Next Year EPS Consensus Estimate: $-0.65 EPS

Dividends

Dividend History for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Insider Ownership Percentage: 11.60%
Institutional Ownership Percentage: 31.78%
Insider Trades by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Institutional Ownership by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Insider Trades by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/11/2017Barbara WhiteInsiderBuy2,479$6.05$14,997.95View SEC Filing  
8/11/2017Sean F MoranCFOBuy2,500$5.91$14,775.00View SEC Filing  
8/11/2017Yuval CohenCEOBuy1,695$6.00$10,170.00View SEC Filing  
5/11/2017Barbara WhiteInsiderBuy2,435$6.12$14,902.20View SEC Filing  
5/11/2017David P HochmanDirectorBuy3,400$6.18$21,012.00View SEC Filing  
5/11/2017Sean F MoranCFOBuy3,300$6.14$20,262.00View SEC Filing  
5/11/2017Yuval CohenCEOBuy3,250$6.01$19,532.50View SEC Filing  
3/17/2017Barbara WhiteInsiderBuy4,233$9.49$40,171.17View SEC Filing  
3/13/2017Sean F MoranCFOBuy2,000$9.60$19,200.00View SEC Filing  
12/2/2016Sean F MoranCFOBuy1,500$7.20$10,800.00View SEC Filing  
11/22/2016Alan F HolmerDirectorBuy1,000$7.49$7,490.00View SEC Filing  
11/22/2016Yuval CohenCEOBuy1,340$7.64$10,237.60View SEC Filing  
11/18/2016David P HochmanDirectorBuy10,000$7.00$70,000.00View SEC Filing  
9/8/2016Sean F MoranCFOBuy30,800$5.12$157,696.00View SEC Filing  
8/26/2016Sean F MoranCFOBuy17,900$3.92$70,168.00View SEC Filing  
8/22/2016David P HochmanDirectorBuy1,800$3.77$6,786.00View SEC Filing  
8/18/2016Sean F MoranCFOBuy148,960$3.32$494,547.20View SEC Filing  
8/17/2016Barbara WhiteInsiderBuy38,000$3.15$119,700.00View SEC Filing  
6/8/2016Barbara WhiteInsiderBuy1,935$3.10$5,998.50View SEC Filing  
6/6/2016Yuval CohenCEOBuy1,500$3.34$5,010.00View SEC Filing  
6/1/2016Barbara WhiteInsiderBuy2,570$3.52$9,046.40View SEC Filing  
5/19/2016Sean F MoranCFOBuy27,250$2.37$64,582.50View SEC Filing  
5/18/2016Sean F MoranCFOBuy30,000$2.39$71,700.00View SEC Filing  
5/18/2016Yuval CohenCEOBuy2,125$2.40$5,100.00View SEC Filing  
12/11/2015Sean F MoranCFOBuy1,000$1.56$1,560.00View SEC Filing  
12/10/2015Sean F MoranCFOBuy1,000$1.61$1,610.00View SEC Filing  
12/9/2015Sean F MoranCFOBuy1,000$1.67$1,670.00View SEC Filing  
12/8/2015Sean F MoranCFOBuy1,000$1.68$1,680.00View SEC Filing  
12/7/2015Sean F MoranCFOBuy1,000$1.69$1,690.00View SEC Filing  
12/4/2015Sean F MoranCFOBuy1,000$1.72$1,720.00View SEC Filing  
12/2/2015Sean F MoranCFOBuy1,000$1.79$1,790.00View SEC Filing  
11/24/2015Sean F MoranCFOBuy1,500$1.78$2,670.00View SEC Filing  
11/20/2015Sean F MoranCFOBuy1,500$1.70$2,550.00View SEC Filing  
11/19/2015Barbara WhiteInsiderBuy4,000$1.67$6,680.00View SEC Filing  
11/18/2015Sean F MoranCFOBuy1,500$1.71$2,565.00View SEC Filing  
11/17/2015Sean F MoranCFOBuy1,500$1.72$2,580.00View SEC Filing  
11/16/2015Sean F MoranCFOBuy2,000$1.69$3,380.00View SEC Filing  
9/16/2015Sean F MoranCFOBuy5,000$2.12$10,600.00View SEC Filing  
9/15/2015Sean F MoranCFOBuy5,000$2.14$10,700.00View SEC Filing  
9/14/2015Sean F MoranCFOBuy5,000$1.96$9,800.00View SEC Filing  
9/11/2015Sean F MoranCFOBuy5,000$1.85$9,250.00View SEC Filing  
9/3/2015Barbara WhiteInsiderBuy10,000$1.84$18,400.00View SEC Filing  
8/25/2015Barbara WhiteInsiderBuy6,000$1.87$11,220.00View SEC Filing  
8/21/2015Barbara WhiteInsiderBuy10,000$2.05$20,500.00View SEC Filing  
8/21/2015Sean F MoranCFOBuy1,400$2.06$2,884.00View SEC Filing  
8/19/2015Sumner BursteinMajor ShareholderSell200,000$3.04$608,000.00View SEC Filing  
8/18/2015Barbara WhiteinsiderBuy20,000$1.90$38,000.00View SEC Filing  
8/18/2015Renu GuptaDirectorBuy10,000$1.89$18,900.00View SEC Filing  
8/18/2015Sean F MoranCFOBuy1,000$1.92$1,920.00View SEC Filing  
8/17/2015Avery W CatlinDirectorBuy11,788$1.94$22,868.72View SEC Filing  
8/17/2015Yuval CohenCEOBuy2,100$1.92$4,032.00View SEC Filing  
7/15/2015Sumner BursteinMajor ShareholderSell30,000$2.82$84,600.00View SEC Filing  
6/15/2015Barbara WhiteInsiderBuy2,250$3.25$7,312.50View SEC Filing  
6/12/2015Barbara WhiteInsiderBuy6,000$3.00$18,000.00View SEC Filing  
6/9/2015Avery W CatlinDirectorBuy20,000$3.10$62,000.00View SEC Filing  
6/9/2015Sean F MoranCFOBuy6,500$3.00$19,500.00View SEC Filing  
12/18/2014Sean F MoranCFOBuy18,800$3.36$63,168.00View SEC Filing  
12/17/2014Sean F MoranCFOBuy2,850$3.46$9,861.00View SEC Filing  
12/11/2014Sean F MoranCFOBuy1,000$3.98$3,980.00View SEC Filing  
12/9/2014Sean F MoranCFOBuy1,700$3.98$6,766.00View SEC Filing  
12/4/2014Barbara WhiteInsiderBuy3,300$3.00$9,900.00View SEC Filing  
12/4/2014David P HochmanDirectorBuy1,300$3.05$3,965.00View SEC Filing  
12/4/2014Sean F MoranCFOBuy2,000$3.20$6,400.00View SEC Filing  
12/3/2014Yuval CohenCEOBuy1,000$3.20$3,200.00View SEC Filing  
12/2/2014Sean F MoranCFOBuy1,000$3.03$3,030.00View SEC Filing  
12/1/2014Barbara WhiteInsiderBuy16,448$3.00$49,344.00View SEC Filing  
11/28/2014Barbara WhiteInsiderBuy19,933$3.00$59,799.00View SEC Filing  
11/26/2014Barbara WhiteInsiderBuy13,400$3.00$40,200.00View SEC Filing  
11/26/2014Sean F MoranCFOBuy1,000$3.05$3,050.00View SEC Filing  
11/25/2014Mark TepperInsiderBuy2,000$3.05$6,100.00View SEC Filing  
11/25/2014Sean F MoranCFOBuy3,000$3.05$9,150.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Latest Headlines for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Source:
DateHeadline
finance.yahoo.com logoCorbus Pharmaceuticals Announces Presentation of Three Abstracts at the 2017 North American Cystic Fibrosis Conference
finance.yahoo.com - September 25 at 12:13 PM
finance.yahoo.com logoCorbus Pharmaceuticals Announces Presentation of Six Abstracts and New Anabasum Data at 2017 ACR Annual Meeting
finance.yahoo.com - September 20 at 6:16 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings, Inc. (CRBP) Receives "Buy" Rating from Cantor Fitzgerald
www.americanbankingnews.com - September 20 at 5:10 PM
finance.yahoo.com logoCorbus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 14 at 6:21 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings, Inc. (CRBP) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - September 14 at 12:56 AM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings, Inc. (CRBP) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 14 at 12:44 AM
finance.yahoo.com logoETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : September 12, 2017
finance.yahoo.com - September 11 at 11:09 PM
finance.yahoo.com logoIs There Now An Opportunity In Corbus Pharmaceuticals Holdings Inc (CRBP)?
finance.yahoo.com - September 11 at 6:07 PM
nasdaq.com logo3 Reasons Momentum Stock Investors Will Love Corbus Pharmaceuticals Holdings (CRBP) - Nasdaq
www.nasdaq.com - September 9 at 10:16 PM
finance.yahoo.com logo3 Reasons Momentum Stock Investors Will Love Corbus Pharmaceuticals Holdings (CRBP)
finance.yahoo.com - September 8 at 5:51 PM
nasdaq.com logoSurging Earnings Estimates Signal Good News for Corbus Pharmaceuticals (CRBP) - Nasdaq
www.nasdaq.com - September 1 at 10:58 PM
finance.yahoo.com logoSurging Earnings Estimates Signal Good News for Corbus Pharmaceuticals (CRBP)
finance.yahoo.com - September 1 at 5:46 PM
finance.yahoo.com logoETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 11:29 PM
finance.yahoo.com logoCorbus Pharmaceuticals to Host Fireside Chat on Dermatomyositis with Expert Physician and Researcher, Victoria Werth, MD
finance.yahoo.com - August 31 at 5:25 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings, Inc. (CRBP) Forecasted to Post FY2017 Earnings of ($0.60) Per Share
www.americanbankingnews.com - August 28 at 3:18 AM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings, Inc. (CRBP) Upgraded to "Sell" by BidaskClub
www.americanbankingnews.com - August 25 at 10:26 PM
benzinga.com logoFrom A(erie) To Z(ynerba): Biotech Catalysts Lined Up For Second ... - Benzinga
www.benzinga.com - August 25 at 3:51 PM
finance.yahoo.com logoCorbus Pharmaceuticals Holdings, Inc. :CRBP-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 5:42 PM
finance.yahoo.com logoCorbus Pharmaceuticals Holdings, Inc. breached its 50 day moving average in a Bearish Manner : CRBP-US : August 15, 2017
finance.yahoo.com - August 15 at 6:11 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Genocea Biosciences and Corbus Pharmaceuticals
finance.yahoo.com - August 11 at 5:56 PM
americanbankingnews.com logoYuval Cohen Purchases 1,695 Shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock
www.americanbankingnews.com - August 11 at 4:44 PM
americanbankingnews.com logoBarbara White Purchases 2,479 Shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock
www.americanbankingnews.com - August 11 at 4:42 PM
americanbankingnews.com logoSean F. Moran Buys 2,500 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Stock
www.americanbankingnews.com - August 11 at 1:40 PM
seekingalpha.com logoCorbus Shining Light On Rare Diseases - Seeking Alpha
seekingalpha.com - August 10 at 11:46 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Announces Quarterly Earnings Results
www.americanbankingnews.com - August 10 at 11:04 PM
reuters.com logoBRIEF-Corbus Pharmaceuticals Holdings reports Q2 loss per share $0.15
www.reuters.com - August 9 at 11:00 PM
finance.yahoo.com logoCorbus Pharmaceuticals reports 2Q loss
finance.yahoo.com - August 9 at 5:40 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) PT Set at $24.00 by Cantor Fitzgerald
www.americanbankingnews.com - August 9 at 1:30 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings, Inc. (CRBP) Given Buy Rating at Noble Financial
www.americanbankingnews.com - August 9 at 9:00 AM
feeds.benzinga.com logoCorbus Pharmaceuticals Reports 2017 Second Quarter Financial Results and Provides Business Update
feeds.benzinga.com - August 9 at 8:35 AM
finance.yahoo.com logoCorbus Pharmaceuticals to Present New Data from Systemic Sclerosis Phase 2 Study of Anabasum at the 15th International Workshop on Scleroderma Research
finance.yahoo.com - August 7 at 5:55 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - August 7 at 7:08 AM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Downgraded by BidaskClub
www.americanbankingnews.com - August 5 at 10:46 PM
finance.yahoo.com logoIt's High Time For The Cannabis-Related Drug Pipeline
finance.yahoo.com - August 3 at 9:42 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - July 29 at 7:20 PM
finance.yahoo.com logoCorbus Pharmaceuticals Holdings, Inc. breached its 50 day moving average in a Bearish Manner : CRBP-US : July 25, 2017
finance.yahoo.com - July 25 at 5:28 PM
finance.yahoo.com logoETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 5:11 PM
finance.yahoo.com logoHow To Profit From Canada’s $22 Billion Marijuana Boom
finance.yahoo.com - July 19 at 11:41 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Rating Reiterated by Cantor Fitzgerald
www.americanbankingnews.com - July 17 at 4:04 PM
finance.yahoo.com logoETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 7:33 PM
prnewswire.com logoCannabinoid Market Growth Expands With Rising Influence of Pharma and Biotech Science Advancements - PR Newswire (press release)
www.prnewswire.com - July 11 at 6:37 PM
finance.yahoo.com logoCorbus Pharmaceuticals Holdings, Inc. – Value Analysis (NASDAQ:CRBP) : July 11, 2017
finance.yahoo.com - July 11 at 6:37 PM
finance.yahoo.com logoCorbus Pharmaceuticals Holdings, Inc. breached its 50 day moving average in a Bullish Manner : CRBP-US : July 10, 2017
finance.yahoo.com - July 10 at 5:30 PM
americanbankingnews.com logoBidaskClub Upgrades Corbus Pharmaceuticals Holdings, Inc. (CRBP) to "Hold"
www.americanbankingnews.com - July 8 at 8:26 PM
thestreet.com logoCommit To Buy Corbus Pharmaceuticals Holdings At $5, Earn 17.2 ... - TheStreet.com
www.thestreet.com - July 7 at 4:53 AM
finance.yahoo.com logoCorbus Pharmaceuticals Announces Inclusion in Russell 3000(R) Index
finance.yahoo.com - June 26 at 5:14 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings, Inc. (CRBP) Expected to Earn FY2018 Earnings of ($0.66) Per Share
www.americanbankingnews.com - June 26 at 10:42 AM
seekingalpha.com logoCorbus Pharmaceuticals Can Hit New Highs By Year's End - Seeking Alpha
seekingalpha.com - June 23 at 10:06 PM
americanbankingnews.com logoNoble Financial Reiterates Buy Rating for Corbus Pharmaceuticals Holdings, Inc. (CRBP)
www.americanbankingnews.com - June 17 at 7:16 AM
streetinsider.com logoCorbus Pharma (CRBP) Announces Data from Phase 2 Study of ... - StreetInsider.com
www.streetinsider.com - June 16 at 4:26 AM

Social

Chart

Corbus Pharmaceuticals Holdings (CRBP) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by MarketBeat.com Staff